PASG - צמיחת מכירות משנה לשנה ב-12 החודשים האחרונים Passage Bio, Inc.

Passage Bio, Inc. (PASG) is developing a non-cyclical gene therapy segment where the demand for innovation remains independent of economic conditions. The TTM revenue growth rate compared to the same period last year demonstrates an upward trend, and the value of 0.00 represents the current metric. Drug development relies on a partnership with the University of Pennsylvania, while modernized biomedical facilities ensure the stability of drug production.

This chart reflects the daily price action of Passage Bio, Inc. (PASG) annual turnover. The YoY revenue growth rate over a rolling 12-month period measures expansion rates by comparing current figures with the same window from the previous year. For a pre-commercial gene therapy developer, this indicator confirms a stage characterized by a lack of regular sales. Growth in this metric will only become possible following successful trials and the implementation of a pricing strategy in the orphan market.